Abstract 179P
Background
The elderly have numerous risk factors, such as comorbidities, undernutrition, and sarcopenia. Therefore, they require careful treatment indications and management in cancer treatment. Body composition and sarcopenia assessment have been performed in gastric cancer preoperative patients to improve perioperative outcomes since 2018, and we have provided nutritional/rehabilitative assessments and medical support to eligible patients with collaborative practice (CP).
Methods
Of 881 patients with gastrectomy between January 2011 and April 2023, aged 80 years or older were included in this study. We compared the short-term perioperative outcomes of patients with preoperative nutritional/rehabilitative assessments and support with CP (supportive (S) group) and without this assessment (non-supportive (NS) group).
Results
Sixty patients in the S group and 103 in the NS group. There were no differences in age, gender, performance status, Charlson comorbidity index, clinical Stage, or preoperative nutritional assessment, but the S group had a higher body mass index (median; S: 22.2 mg/m2 vs. NS: 21.5 mg/m2, p=0.02) and higher ASA-PS (ASA-PS ≥3, S: 48.4 vs. NS: 24.8%, p=0.002). The S group had fewer total gastrectomies (S: 15.0% vs. NS: 29.1%, p=0.037) and more robotic/laparoscopic approaches (S: 75.0% vs. NS: 30.1%, p<0.001). There was no difference in operative time but less blood loss in the S group (S: 50ml vs. NS: 230ml, p<0.001). Overall complications were lower in the S group (S: 20.0% vs. NS: 36.9%, p=0.021), but there was no difference in Clavien-Dindo ≥3 or higher complications (S: 6.7% vs. NS: 12.6%, p=0.21). In particular, the S group had fewer surgical site infections (S: 6.7% vs. NS: 17.5%, p=0.041) and pneumonia (S: 3.3% vs. NS: 15.5%, p=0.009). Postoperative hospital stay was shorter in the S group (S: 11 days vs. NS: 16 days, p<0.001).
Conclusions
Our results suggest that pre-operative nutritional/rehabilitative assessments and support in elderly gastric cancer patients led to fewer postoperative infectious complications and shorter hospital stays.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sakai City Medical Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract